ATOS
Price
$0.88
Change
+$0.04 (+4.76%)
Updated
May 13, 04:59 PM (EDT)
Capitalization
114.96M
5 days until earnings call
LCTX
Price
$0.47
Change
-$0.01 (-2.08%)
Updated
May 13, 04:59 PM (EDT)
Capitalization
107.33M
85 days until earnings call
Ad is loading...

ATOS vs LCTX

Header iconATOS vs LCTX Comparison
Open Charts ATOS vs LCTXBanner chart's image
Atossa Therapeutics
Price$0.88
Change+$0.04 (+4.76%)
Volume$2.18K
Capitalization114.96M
Lineage Cell Therapeutics
Price$0.47
Change-$0.01 (-2.08%)
Volume$21.91K
Capitalization107.33M
ATOS vs LCTX Comparison Chart
Loading...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LCTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATOS vs. LCTX commentary
May 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATOS is a StrongBuy and LCTX is a Hold.

Ad is loading...
COMPARISON
Comparison
May 14, 2025
Stock price -- (ATOS: $0.84 vs. LCTX: $0.48)
Brand notoriety: ATOS and LCTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATOS: 86% vs. LCTX: 63%
Market capitalization -- ATOS: $114.96M vs. LCTX: $107.33M
ATOS [@Biotechnology] is valued at $114.96M. LCTX’s [@Biotechnology] market capitalization is $107.33M. The market cap for tickers in the [@Biotechnology] industry ranges from $295.2B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATOS’s FA Score shows that 1 FA rating(s) are green whileLCTX’s FA Score has 0 green FA rating(s).

  • ATOS’s FA Score: 1 green, 4 red.
  • LCTX’s FA Score: 0 green, 5 red.
According to our system of comparison, LCTX is a better buy in the long-term than ATOS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATOS’s TA Score shows that 6 TA indicator(s) are bullish while LCTX’s TA Score has 6 bullish TA indicator(s).

  • ATOS’s TA Score: 6 bullish, 4 bearish.
  • LCTX’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, LCTX is a better buy in the short-term than ATOS.

Price Growth

ATOS (@Biotechnology) experienced а -4.88% price change this week, while LCTX (@Biotechnology) price change was +4.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.49%. For the same industry, the average monthly price growth was +10.87%, and the average quarterly price growth was -7.60%.

Reported Earning Dates

ATOS is expected to report earnings on Aug 18, 2025.

LCTX is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+1.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATOS($115M) has a higher market cap than LCTX($107M). LCTX YTD gains are higher at: -4.657 vs. ATOS (-11.355). LCTX has higher annual earnings (EBITDA): -20.87M vs. ATOS (-29.46M). ATOS has more cash in the bank: 74.8M vs. LCTX (47.8M). ATOS has less debt than LCTX: ATOS (0) vs LCTX (2.51M). LCTX has higher revenues than ATOS: LCTX (9.5M) vs ATOS (0).
ATOSLCTXATOS / LCTX
Capitalization115M107M107%
EBITDA-29.46M-20.87M141%
Gain YTD-11.355-4.657244%
P/E RatioN/AN/A-
Revenue09.5M-
Total Cash74.8M47.8M156%
Total Debt02.51M-
FUNDAMENTALS RATINGS
ATOS vs LCTX: Fundamental Ratings
ATOS
LCTX
OUTLOOK RATING
1..100
87
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
37
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
5365
P/E GROWTH RATING
1..100
10062
SEASONALITY SCORE
1..100
95n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATOS's Valuation (28) in the Medical Specialties industry is in the same range as LCTX (37) in the null industry. This means that ATOS’s stock grew similarly to LCTX’s over the last 12 months.

ATOS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as LCTX (100) in the null industry. This means that ATOS’s stock grew similarly to LCTX’s over the last 12 months.

ATOS's SMR Rating (96) in the Medical Specialties industry is in the same range as LCTX (96) in the null industry. This means that ATOS’s stock grew similarly to LCTX’s over the last 12 months.

ATOS's Price Growth Rating (53) in the Medical Specialties industry is in the same range as LCTX (65) in the null industry. This means that ATOS’s stock grew similarly to LCTX’s over the last 12 months.

LCTX's P/E Growth Rating (62) in the null industry is somewhat better than the same rating for ATOS (100) in the Medical Specialties industry. This means that LCTX’s stock grew somewhat faster than ATOS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATOSLCTX
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 6 days ago
76%
Declines
ODDS (%)
Bearish Trend 6 days ago
89%
Bearish Trend 8 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LCTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA318.3820.12
+6.75%
Tesla
AAPL210.7912.52
+6.31%
Apple
SPY582.9918.65
+3.30%
SPDR® S&P 500® ETF
GME28.050.51
+1.85%
GameStop Corp
BTC.X102812.950000-1293.406200
-1.24%
Bitcoin cryptocurrency

ATOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATOS has been loosely correlated with ABOS. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ATOS jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATOS
1D Price
Change %
ATOS100%
+2.47%
ABOS - ATOS
55%
Loosely correlated
+7.13%
GBIO - ATOS
48%
Loosely correlated
+8.44%
ABCL - ATOS
48%
Loosely correlated
+1.48%
ERAS - ATOS
48%
Loosely correlated
N/A
PDSB - ATOS
46%
Loosely correlated
+7.50%
More

LCTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LCTX has been loosely correlated with ATOS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if LCTX jumps, then ATOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LCTX
1D Price
Change %
LCTX100%
+8.89%
ATOS - LCTX
42%
Loosely correlated
+2.47%
ABCL - LCTX
37%
Loosely correlated
+1.48%
VTGN - LCTX
37%
Loosely correlated
+3.57%
ATAI - LCTX
36%
Loosely correlated
+3.60%
ABSI - LCTX
34%
Loosely correlated
+6.55%
More